Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005647-24
    Sponsor's Protocol Code Number:MIA2019/CT/258_ABC-X
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2025-02-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-005647-24
    A.3Full title of the trial
    A PHASE II, OPEN LABEL, RANDOMISED TRIAL OF IPILIMUMAB AND NIVOLUMAB WITH CONCURRENT INTRACRANIAL STEREOTACTIC RADIOTHERAPY VERSUS IPILIMUMAB AND NIVOLUMAB ALONE IN PATIENTS WITH MELANOMA BRAIN METASTASES.
    UNO STUDIO RANDOMIZZATO DI FASE II, IN APERTO, DI IPILIMUMAB E NIVOLUMAB CON CONCOMITANTE RADIOTERAPIA STEREOTASSICA INTRACRANICA RISPETTO A IPILIMIMUAB E NIVOLUMAB DA SOLI IN PAZIENTI CON METASTASI CEREBRALI DA MELANOMA.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A PHASE II, OPEN LABEL, RANDOMISED TRIAL OF IPILIMUMAB AND NIVOLUMAB WITH CONCURRENT INTRACRANIAL STEREOTACTIC RADIOTHERAPY VERSUS IPILIMUMAB AND NIVOLUMAB ALONE IN PATIENTS WITH MELANOMA BRAIN METASTASES.
    UNO STUDIO RANDOMIZZATO DI FASE II, IN APERTO, DI IPILIMUMAB E NIVOLUMAB CON CONCOMITANTE RADIOTERAPIA STEREOTASSICA INTRACRANICA RISPETTO A IPILIMIMUAB E NIVOLUMAB DA SOLI IN PAZIENTI CON METASTASI CEREBRALI DA MELANOMA.
    A.3.2Name or abbreviated title of the trial where available
    Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study
    Collaborazione Anti-PD-1 sul Cervello + Estensione della Radioterapia: Lo Studio ABC-X
    A.4.1Sponsor's protocol code numberMIA2019/CT/258_ABC-X
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMelanoma Institute Australia
    B.1.3.4CountryAustralia
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportbristol myers squibb research and development Pty Ltd
    B.4.2CountryAustralia
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIstituto Nazionale Tumori - IRCCS Fondazione Pascale
    B.5.2Functional name of contact pointSC OMITI
    B.5.3 Address:
    B.5.3.1Street AddressVia Mariano Semmola
    B.5.3.2Town/ cityNapoli
    B.5.3.3Post code80131
    B.5.3.4CountryItaly
    B.5.6E-mailp.ascierto@istitutotumori.na.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB
    D.3.2Product code [NIVOLUMAB]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeBMS-936558
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNivolumab
    D.3.2Product code [Nivolumab]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNivolumab
    D.3.9.2Current sponsor codeBMS-936558
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIpilimumab
    D.3.2Product code [BMS-734016]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNipilimumab
    D.3.9.2Current sponsor codeBMS-734016
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Melanoma with brain metastases
    melanoma con metastasi cerebrali
    E.1.1.1Medical condition in easily understood language
    Melanoma with brain metastases
    melanoma con metastasi cerebrali
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 27.0
    E.1.2Level LLT
    E.1.2Classification code 10027481
    E.1.2Term Metastatic melanoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. One-year neurologic-specific mortality rate
    1. Tasso di morte neurologico-specifico a 1 anno
    E.2.2Secondary objectives of the trial
    Secondary:
    1. Intracranial response rate
    2. Extracranial response rate
    3. Overall response rate
    4. Progression-free survival
    5. Non-neurological death at 1 year
    6. Overall survival
    7. Incidence of radionecrosis up to 5 years from the start of any intracranial radiotherapy
    8. Incidence of salvage radiotherapy for intracranial disease in both cohorts
    9. Incidence of salvage surgery for intracranial disease in both cohorts
    10. Neurocognitive function - assessed by the investigator (MoCA) and by the patient (FACT-cog)
    11. Quality of life assessed by the patient (QLQ C30, QLQ-BN20, EQ-5D, and FACT-Br)
    12. Functional performance status (ECOG)
    13. Overall safety and tolerability of study treatments (CTCAE version 5.0)
    14. Tissue, blood, stool, and urine biomarkers of treatment response, disease progression, and treatment toxicity.
    Secondari:
    1. Tasso di risposta intracranica
    2. Tasso di risposta extracranica
    3. Tasso di risposta globale
    4. Sopravvivenza globale libera da progressione
    5. Morte non neurologica a 1 anno
    6. Sopravvivenza globale
    7. Incidenza di radionecrosi fino a 5 anni dall'inizio di qualsiasi radioterapia intracranica
    8. Incidenza della radioterapia di salvataggio per la malattia intracranica in entrambe le coorti
    9. Incidenza della chirurgia di salvataggio per la malattia intracranica in entrambe le coorti
    10. Funzione neurocognitiva - valutata dal ricercatore (MoCA) e dal paziente (FACT-cog)
    11. Qualità della vita valutata dal paziente (QLQ C30, QLQ-BN20, EQ-5D e FACT-Br)
    12. Performance status funzionale (ECOG)
    13. Sicurezza generale e tollerabilità dei trattamenti dello studio (CTCAE versione 5.0)
    14. Biomarcatori tissutali, ematici, delle feci e delle urine della risposta al trattamento
    sistemico e locale, della progressione della malattia e della tossicità del trattamento.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. =18 years of age.
    2. Written informed consent.
    3. AJCC Stage IV melanoma (any T, any N, M1d) confirmed histologically, including cutaneous, acral, or mucosal melanoma, or unknown primary melanoma, with brain metastases considered unresectable. Patients must have at least one measurable brain metastasis (= 5mm and =40mm) based on radiological findings according to RECIST bm guidelines. There is no maximum limit on the number of brain metastases.
    4. BRAF mutation status prior to randomization.
    5. The treating physician should consider all intracranial lesions (target and non-target) suitable for stereotactic radiotherapy versus whole brain radiotherapy. This includes brain metastases with a diameter of =5mm.
    6. No prior radiotherapy for brain metastases (previous brain metastasis surgery is allowed). Prior radiotherapy for extracranial disease is allowed.
    7. No prior systemic therapy for melanoma unless administered in the neoadjuvant or adjuvant setting and only for extracranial disease treatment. There must be documented radiological confirmation of the absence of brain metastases during prior systemic therapy. The current diagnosis of brain metastases must have occurred = 6 months after the discontinuation of systemic therapy (previous PD1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, BRAF/MEK inhibitors, or clinical trial agents are acceptable in the context of neoadjuvant or adjuvant therapy).
    8. Asymptomatic from brain metastases at the time of study enrollment without corticosteroids, analgesics, or any other treatment for managing neurological symptoms (except for antiepileptic drugs prescribed for any reason, as long as the patient is asymptomatic). Resolved neurological symptoms are allowed if complete resolution, without any intervention, has been maintained for at least 7 days before randomization.
    9. ECOG performance status of 0-2.
    10. Life expectancy > 30 days.
    11. Able to undergo MRI with gadolinium contrast.
    12. Adequate hematologic, hepatic, and renal organ function.
    13. Women of childbearing potential with a negative pregnancy test and effective contraception.
    14. Men with a female partner of childbearing potential who use effective contraception and refrain from sperm donation during the study and for 31 weeks after the end of treatment.
    1. =18 anni di età.
    2. Consenso scritto informato
    3. AJCC Stage AJCC Stage IV (qualsiasi T, qualsiasi N, M1d) melanoma cutaneo, acrale o
    mucoso confermato istologicamente, o melanoma primario sconosciuto, con metastasi al
    cervello che sono considerate non resecabili. I pazienti devono avere un minimo di una
    metastasi cerebrale definitiva radiologica che sia = 5mm e =40mm, misurabile secondo le
    linee guida RECIST bm. Non c'è un limite massimo al numero di metastasi cerebrali.
    4. Stato della mutazione BRAF prima della randomizzazione
    5. Il medico curante dovrebbe considerare tutte le lesioni intracraniche (target e non
    target) suscettibili di radioterapia stereotassica rispetto alla radioterapia del cervello
    intero. Questo include metastasi cerebrali di diametro =5mm.
    6. Nessuna radioterapia precedente per metastasi cerebrali (è permesso un
    precedente intervento chirurgico per metastasi cerebrali da melanoma). La
    radioterapia precedente per la malattia extracranica è consentita.
    7. Nessuna precedente terapia farmacologica sistemica per il melanoma, a meno che non
    sia stata somministrata in ambito neo adiuvante o adiuvante e solo per il trattamento
    della malattia extracranica. Deve essere documentata la conferma radiologica
    dell'assenza di metastasi cerebrali durante il precedente trattamento sistemico. La
    diagnosi attuale di metastasi cerebrali deve essere avvenuta.
    = 6 mesi dopo l'interruzione della terapia sistemica (precedenti inibitori anti PD1, anti PD L1, anti CTLA-4, BRAF/MEK o agenti di sperimentazione clinica sono accettabili nell'ambito
    del trattamento neo adiuvante o adiuvante).
    8. Asintomatico da metastasi cerebrali al momento dell'arruolamento nello studio senza
    corticosteroidi, analgesia o qualsiasi altro trattamento per la gestione dei sintomi
    neurologici (ad eccezione degli antiepilettici prescritti per qualsiasi motivo, purché il
    paziente sia asintomatico). I sintomi neurologici risolti sono consentiti se la risoluzione
    completa, senza alcun intervento, è stata sostenuta per un minimo di 7 giorni prima della
    randomizzazione.
    9. ECOG performance status di 0-2.
    10. aspettativa di vita > 30 giorni.
    11. In grado di sottoporsi a risonanza magnetica con mezzo di contrasto Gadolinio.
    12. Adeguata funzione ematologica, epatica e renale degli organi.
    13. Donne in età fertile con un test di gravidanza negativo, contraccezione efficace.
    14. Gli uomini con una partner femminile con potenziale di gravidanza che usano una
    contraccezione efficace e si astengono dal donare lo sperma durante lo studio e per 31
    settimane dalla fine del trattamento.
    E.4Principal exclusion criteria
    1. Patients whose intracranial disease changes between the eligibility MRI and the SRS planning MRI, making the patient unsuitable for randomized treatment in the study or requiring alternative specific treatment.
    2. Any melanoma brain metastasis >40mm.
    3. Evidence of leptomeningeal disease, except for pathological findings seen during a previous resection of brain disease, with no evidence of leptomeningeal disease elsewhere at the time of resection or at study entry.
    4. Ocular melanoma (both uveal and conjunctival) (mucosal and acral melanoma are eligible).
    5. Current neurological symptoms from brain metastases or a requirement for corticosteroids, analgesics, or other treatments for symptom management.
    6. Previous brain radiotherapy (previous brain metastasis surgery for melanoma is allowed).
    7. Previous systemic therapy for melanoma, unless it was administered in the neoadjuvant or adjuvant setting, before the development of any brain metastases and completed = 6 months before enrollment in this study.
    8. Patients with significant active, known, or suspected autoimmune disease requiring past or current immunosuppression.
    9. Current systemic treatment with corticosteroids, or within 7 days of randomization, except for prednisone at non-immunosuppressive doses of = 10 mg/day (or equivalent).
    10. Active infection requiring treatment.
    11. History of interstitial lung disease.
    12. Any concurrent malignancy (excluding in situ disease, basal cell carcinoma, and squamous cell carcinoma of the skin) requiring any treatment or a history of another malignancy, unless the patient has been disease-free for 1 year.
    13. Severe or unstable pre-existing medical conditions or other conditions that could interfere with patient safety, consent, or compliance.
    14. Pregnant or breastfeeding females.
    15. Administration of any form of live vaccine within 30 days prior to the start of the trial and during the trial. The use of other vaccines is cautioned within 30 days prior to the start of the trial and during the treatment phase of the trial.
    1. Pazienti la cui malattia intracranica cambia tra la risonanza magnetica di ammissibilità e la
    risonanza magnetica di pianificazione SRS, rendendo il paziente inadatto al trattamento
    randomizzato nello studio, o richiede un trattamento alternativo specifico.
    2. Qualsiasi metastasi cerebrali di melanoma >40mm.
    3. Evidenza di malattia leptomeningea, ad eccezione dei risultati patologici visti in occasione
    di una precedente resezione della malattia cerebrale, ma nessuna evidenza di malattia
    leptomeningea altrove al momento della resezione o all'ingresso dello studio.
    4. Melanoma oculare (sia uveale che congiuntivale) (il melanoma mucoso e acrale
    sono ammissibili).
    5. Attuali sintomi neurologici da metastasi cerebrali o una richiesta di
    corticosteroidi, analgesia o altri trattamenti per la gestione dei sintomi.
    6. Radioterapia precedente al cervello (è permesso un precedente intervento chirurgico
    per metastasi cerebrali da melanoma)
    7. Una precedente terapia sistemica per il melanoma, a meno che non sia stata
    somministrata in ambito neo adiuvante o adiuvante, prima dello sviluppo di qualsiasi
    metastasi cerebrale e completata = 6 mesi prima dell'arruolamento in questo studio.
    8. Pazienti con una significativa malattia autoimmune attiva, nota o sospetta, che richiede
    immunosoppressione passata o attuale.
    9. Trattamento sistemico attuale con corticosteroidi, o entro 7 giorni dalla
    randomizzazione, eccetto prednisone a dosi non immunosoppressive di = 10
    mg/giorno (o equivalente).
    10. Infezione attiva che richiede una terapia.
    11. Storia di malattia polmonare interstiziale.
    12. Qualsiasi malignità concomitante (esclusa la malattia in situ, il carcinoma a cellule basali
    e il carcinoma a cellule squamose della pelle) che richiede un qualsiasi trattamento o una
    storia di un'altra malignità, a meno che il paziente sia stato libero da malattia per 1 anno.
    13. Condizioni mediche preesistenti gravi o instabili o altre condizioni che potrebbero
    interferire con la sicurezza, il consenso o la conformità del paziente.
    14. Femmine incinte o che allattano.
    15. Somministrazione di qualsiasi forma di vaccino vivo entro 30 giorni dall'inizio della
    sperimentazione e durante la sperimentazione. L'uso di altri vaccini è cautelativo entro
    30 giorni dall'inizio della sperimentazione e durante la fase di trattamento della
    sperimentazione.
    E.5 End points
    E.5.1Primary end point(s)
    The incidence of neurologic-specific death in the entire patient population at 1 year from the start of nivolumab and ipilimumab, where the immediate cause of death is due to brain metastases.
    L'incidenza di morte neurologica specifica nell'intera popolazione di pazienti a 1 anno dall'inizio d nivolumab e ipilimumab, dove la causa immediata di morte è dovuta a metastasi cerebrali.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 year from the start of treatment with nivolumab and ipilimumab.
    1 anno dall'inizio del trattamento con nivolumab e ipilimumab
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA2
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years10
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years10
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 20
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 60
    F.4.2.2In the whole clinical trial 218
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    nessuno
    nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-04-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-12-21
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:08:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA